Abstract: OBJECTIVE To explore the clinical efficacy and pharmaceutical economics of different dosing regimens of cefoperazone sodium and sulbactam sodium. METHODS The values of %T>MIC of different dosing regimens were calculated by referencing the pharmacokinetic parameters of drug introductions and drug sensitive MIC interpretation standard of Clinical and Laboratory Standards Institute. The clinical efficacy and pharmaceutical economics was evaluated by the standard of (%T>MIC)≥50%. The drug resistance of commonly used antibiotics of our hospital in the 8 years was analysed. RUSULTS Scheme of (%T>MIC)≥50%: ①1.5 g, q12h group was sensitive grade; ②1.5 g, q8h, 3.0 g, q12h groups were sensitive, medium level; ③1.5 g, q6h, 3.0 g, q8h and 3.0 g, q6h groups were sensitive, medium and drug resistance. The (%T>MIC) values were basically similar between the 3.0 q8h group and 1.5 q6h group, but 1.5 q6h group was more cheap and efficient. Cefoperazone sodium and sulbactam sodium was used to treat 59 cases. The over instruction rate was 89.83%. The total effective rate was 79.24%. CONCLUSION The drug regimen(q12h) of drug introduction of cefoperazone sodium and sulbactam sodium can not meet the needs of clinical treatment under the situation of serious bacteria resistance. Severe or multiple drug resistant bacterial infections must be administered by q6-8h. The research and legislation of off-label drug use are imperative.